116 related articles for article (PubMed ID: 17538157)
1. Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions.
Forastiere AA; Burtness BA
J Clin Oncol; 2007 Jun; 25(16):2152-5. PubMed ID: 17538157
[No Abstract] [Full Text] [Related]
2. Targeting the future in head and neck cancer.
Brizel DM
Lancet Oncol; 2009 Mar; 10(3):204-5. PubMed ID: 19261251
[No Abstract] [Full Text] [Related]
3. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
4. EGFR-targeted therapeutics: focus on SCCHN and NSCLC.
Sattler M; Abidoye O; Salgia R
ScientificWorldJournal; 2008 Sep; 8():909-19. PubMed ID: 18836658
[TBL] [Abstract][Full Text] [Related]
5. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
Karamouzis MV; Grandis JR; Argiris A
JAMA; 2007 Jul; 298(1):70-82. PubMed ID: 17609492
[TBL] [Abstract][Full Text] [Related]
6. [Role of targeted therapy in the treatment of squamous cell head and neck cancer].
Gyergyay F
Magy Onkol; 2007; 51(2):155-7. PubMed ID: 17660872
[TBL] [Abstract][Full Text] [Related]
7. Treatment of advanced head and neck cancer with cetuximab.
Merlano M; Garrone O
Int J Biol Markers; 2007; 22(1 Suppl 4):S71-6. PubMed ID: 17520584
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab and radiotherapy for head and neck cancer.
Posner MR; Wirth LJ
N Engl J Med; 2006 Feb; 354(6):634-6. PubMed ID: 16467552
[No Abstract] [Full Text] [Related]
9. More on cetuximab in head and neck cancer.
Mell LK; Weichselbaum RR
N Engl J Med; 2007 Nov; 357(21):2201-2; author reply 2202-3. PubMed ID: 18032774
[No Abstract] [Full Text] [Related]
10. EGFR inhibition as a therapy for head and neck squamous cell carcinoma.
Loeffler-Ragg J; Schwentner I; Sprinzl GM; Zwierzina H
Expert Opin Investig Drugs; 2008 Oct; 17(10):1517-31. PubMed ID: 18808311
[TBL] [Abstract][Full Text] [Related]
11. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.
Curran D; Giralt J; Harari PM; Ang KK; Cohen RB; Kies MS; Jassem J; Baselga J; Rowinsky EK; Amellal N; Comte S; Bonner JA
J Clin Oncol; 2007 Jun; 25(16):2191-7. PubMed ID: 17538164
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab and cisplatin for chemotherapy-refractory squamous cell cancer of the head and neck.
Burtness B
J Clin Oncol; 2005 Aug; 23(24):5440-2. PubMed ID: 16009959
[No Abstract] [Full Text] [Related]
13. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.
Yonesaka K; Zejnullahu K; Lindeman N; Homes AJ; Jackman DM; Zhao F; Rogers AM; Johnson BE; Jänne PA
Clin Cancer Res; 2008 Nov; 14(21):6963-73. PubMed ID: 18980991
[TBL] [Abstract][Full Text] [Related]
14. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
15. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.
Herbst RS; Hong WK
Semin Oncol; 2002 Oct; 29(5 Suppl 14):18-30. PubMed ID: 12422310
[TBL] [Abstract][Full Text] [Related]
16. The epidermal growth factor receptor in squamous cell carcinoma: An emerging drug target.
Gaffney DC; Soyer HP; Simpson F
Australas J Dermatol; 2014 Feb; 55(1):24-34. PubMed ID: 23425099
[TBL] [Abstract][Full Text] [Related]
17. Targeting the epidermal growth factor receptor in colorectal carcinoma.
Kurtin SE
Cancer Nurs; 2007; 30(4 Suppl 1):S1-9. PubMed ID: 17666985
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor targeted therapies for solid tumours.
Van den Eynde M; Baurain JF; Mazzeo F; Machiels JP
Acta Clin Belg; 2011; 66(1):10-7. PubMed ID: 21485758
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines.
Yamatodani T; Ekblad L; Kjellén E; Johnsson A; Mineta H; Wennerberg J
J Cancer Res Clin Oncol; 2009 Mar; 135(3):395-402. PubMed ID: 18813952
[TBL] [Abstract][Full Text] [Related]
20. [Chemotherapy for patients with local-regional recurrent or metastatic carcinoma of the head and neck].
Dufresne A; Gainet M; Stein U; Guardiola E; Pivot X
Bull Cancer; 2003 Jan; 90(1):39-45. PubMed ID: 12609803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
